For a deep tech founder approaching a Series A raise, intellectual property is not a legal checkbox—it is the asset investors are pricing. Venture capitalists evaluating deep technology companies scrutinize the strength and scope of the patent portfolio, whether trade secrets have been protected with reasonable measures, and whether the company actually owns everything it claims to sell. A portfolio that satisfies those three tests becomes a fundraising weapon; one that fails any of them becomes a red flag that can cost leverage at the term sheet stage.
The Strategic Imperative of IP for Deep Tech Funding
Deep tech companies are valued primarily on intangible assets: the patents, trade secrets, and proprietary data that underpin the technology. Guidance aimed at IP-backed startups argues that founders who treat IP as a legal task to complete, rather than a strategic pillar of the fundraising narrative, "spectacularly fail to leverage their IP." To a specialist investor, the same guidance contends, an IP strategy signals business acumen, technical depth, and the ability to build a durable monopoly around the invention.
That framing matters because investors do not simply verify that patents exist. Reporting on venture capital due diligence in the life sciences—where IP scrutiny is similarly intense—describes investors evaluating the strength, scope, and strategic positioning of the entire portfolio, and relying on strong IP to assess valuation, risk, and commercialization potential. The same principle extends to deep tech broadly: the portfolio is evidence of defensibility, and defensibility is what justifies the price.
Key IP Types for Deep Tech: Patents vs. Trade Secrets
Two forms of IP dominate deep tech valuation. The first is the utility patent, which startup fundraising guidance describes as a roughly twenty-year government-granted monopoly on how an invention works—a new chemical process, a machine learning method, a machine. For deep tech and biotech, this is characterized as the gold standard, because it gives investors a legally enforceable commercial exclusion that aligns with the business model.
The second is the trade secret, whose value is derived entirely from being kept secret. Trade secrets can protect material that is difficult or impossible to patent—model architecture, training data, processes—but they carry a different burden: protection lasts only as long as the company takes reasonable steps to preserve confidentiality. Investors weigh the two differently. Patents are scrutinized for breadth and enforceability; trade secrets are scrutinized for whether the company has actually kept them secret. A deep tech startup typically needs both, layered so that each asset contributes to the competitive barrier.
Venture Capital Due Diligence: What Investors Scrutinize
Before committing capital, investors run IP due diligence across three broad areas. First, portfolio strength: whether patent applications are broad, enforceable, and capable of withstanding challenges, and whether the portfolio aligns with long-term commercialization goals rather than existing for its own sake. Second, protection discipline: whether trade secrets have been handled in ways that preserve their legal status. Third, ownership: whether the company holds clear title to every piece of IP it relies on, free of encumbrances.
Legal practitioners who conduct this diligence describe the process as comprehensive disclosure of every individual who contributed to the IP, with review of employment contracts, contractor agreements, IP assignment agreements, and third-party service provider agreements. They also check for encumbrances—licenses, disputes, or third-party rights—that can significantly affect the IP's value and usability. The consistent message from diligence professionals is that problems found early can usually be fixed, indemnified, escrowed, or priced; found late, they cost leverage.
Building a Robust Patent Portfolio for Investor Appeal
A patent portfolio that impresses investors is not necessarily a large one—it is one whose claims map onto the business. Investors look for broad claims that cover the core invention and its foreseeable variants, applications positioned to withstand challenges, and a clear relationship between what is patented and what the company intends to commercialize. Due diligence guidance for venture funding emphasizes that investors assess whether the portfolio offers a competitive edge and aligns with commercialization milestones, not merely whether filings exist.
For founders, the practical implication is that patent strategy should be built backward from the business model. A patent on a mechanism the company will never use adds cost without defensibility; a patent on the mechanism competitors must copy to compete is the asset investors will pay for. Founders should be prepared to articulate, claim by claim, how each filing supports the moat.
Safeguarding Trade Secrets: Investor Expectations for Protection
Trade secret diligence is where deep tech companies most often stumble. Attorneys who handle Series A IP preparation report that a company sharing its model architecture, training data, or core algorithms with vendors, partners, or potential customers without non-disclosure agreements "has been diluting its trade secret protection every time it did so"—and that this is one of the most common findings in due diligence for AI and deep tech companies. It is also, they note, entirely avoidable.
The investor test is whether reasonable steps have been taken to keep the material secret. In practice that means NDAs before sensitive disclosures, controlled internal access, and discipline about what is shared with outside parties. Because trade secret status depends on conduct rather than registration, a history of casual disclosure can permanently weaken an asset, and no filing can restore it.
Ensuring Clear IP Ownership and Assignment
Ownership failures are the most damaging category because they can mean the company does not own the technology it is selling. Series A preparation guidance identifies a frequent oversight: IP that founders created before incorporation—code, designs, prototypes, business methods—must be formally assigned to the company in writing. If a founder built the core technology before incorporation and never signed a formal assignment, that technology may legally belong to the founder individually, meaning investors would be funding a company that does not own its own product.
Contractor-created IP presents a parallel risk. Technology lawyers warn that independent contractors and consultants require explicit written assignment of IP rights, and that a company whose core platform was partially developed by contractors without proper assignments may not actually own the technology it purports to sell or license. Diligence also extends to third-party IP: investors will examine whether the product incorporates outside intellectual property and whether the rights to use it are properly documented. Founders who pass smoothly, the Series A guidance observes, are those who treated IP ownership and protection as operational priorities from the beginning rather than scrambling after a term sheet arrived.
Deep Tech IP Readiness Checklist for Series A Funding
Use this matrix to audit your portfolio against the criteria investors apply. For each row, mark whether your startup clearly satisfies the investor expectation, partially satisfies it, or fails it—then treat every "partial" or "fail" as a pre-raise action item.
| IP Area | What Investors Verify | Red Flag If Missing |
|---|---|---|
| Utility patents | Claims are broad, enforceable, and aligned with the commercialization path | Patents exist but do not map to the business model or core invention |
| Trade secrets | Reasonable protection measures, including NDAs before sharing architecture, data, or algorithms | Core technical assets shared with vendors, partners, or customers without NDAs |
| Founder IP assignment | Written assignment of all pre-formation IP to the company | Core technology legally belongs to a founder as an individual |
| Contractor IP assignment | Explicit written assignment of IP from every contractor and consultant | Company may not own platform components built by outside parties |
| Third-party IP | Documented rights to any outside IP incorporated in the product | Undocumented reliance on third-party technology |
| Encumbrances | No undisclosed licenses, disputes, or third-party rights affecting the IP | Encumbrances discovered mid-diligence that reduce the IP's value or usability |
Interpreting the result is straightforward. A portfolio that satisfies the patent, trade secret, and ownership rows is positioned as a fundraising asset: it demonstrates a durable moat and clean title, which supports valuation and de-risks the deal. Any failure in the ownership rows is the most urgent, because it can mean the company does not own what it sells. Failures in the trade secret row are common but, as diligence practitioners note, avoidable if addressed before disclosures multiply.
Aligning IP Strategy with Investor Expectations
Deep tech founders should proactively audit and strengthen their IP portfolio—focusing on patent breadth and commercial alignment, trade secret protection discipline, and clear ownership chains—before engaging with Series A investors, because diligence problems found early can be fixed or priced while those found late cost leverage. The measurable indicator of readiness is successful completion of an internal IP audit using investor-centric criteria, resulting in a documented plan for addressing identified weaknesses before engaging with Series A investors. Founders who reach that point enter fundraising with a portfolio they can defend claim by claim, and a diligence file that holds up under disclosure.
